An adult penis with an erect length of less than 7 cm (2.8 in), but otherwise formed normally, is referred to in medicine as a micropenis. Studies
While results vary slightly across reputable studies, the consensus is that the mean human penis, when erect, is in the range 12.9–15 cm (5.1–5.9 in) in length. A 2015 systematic review published by Veale et al. of medical research on the topic over the previous 30 years published in BJU International showed similar results, giving mean flaccid, stretched non-erect, and erect lengths of 9.16 cm, 13.24 cm, and 13.12 cm respectively, and mean flaccid and erect circumferences of 9.31 cm and 11.66 cm respectively. Erect lengths in the included studies were measured by pushing the pre-pubic fat pad to the bone, and flaccid or erect girth (circumference) was measured at the base or mid-shaft of the penis. Length
Flaccid
One study (published in 1996) found the mean flaccid penis length to be 3.5 inches (8.9 cm) (measured by staff). A review of several studies found average flaccid length to be 9–10 cm (3.5–3.9 in). Length of the flaccid penis does not necessarily correspond to length of the erect penis; some smaller flaccid penises grow much longer, while some larger flaccid penises grow comparatively less.The penis and scrotum can contract involuntarily in reaction to cold temperatures, anxious or nervous level and participation in sports. This decrease of flaccid penis size is referred to by the slang term "shrinkage", due to action by the cremaster muscle.
The source of this growth was the company’s strategy of purchasing under-marketed consumer brands and aggressively marketing those in its portfolio. In 1993, Chattem experienced a 14% decline in sales from the loss of Warner-Lambert’s Rolaids business. To fund a one-time special dividend in 1994, $75 million in high-yield bonds were issued. In January 2013, Chattem acquired the full rights to Rolaids, which had seen its brand wounded under the ownership of Johnson & Johnsons McNeil Consumer Healthcare with a series of product recalls and quality control issues throughout 2010 that ended with most of the Rolaids line discontinued. In September, 2013 Chattem returned Rolaids to the market with new trade dress, though production of Rolaids is not expected to return to Chattanooga. In March 2014, Chattem sold Dexatrim to NVE Pharmaceuticals. Recent events
In October 2006, Chattem announced it would acquire five brands for $410 million as a result of the merger between Johnson & Johnson and the consumer healthcare business of Pfizer. These brands are:

ACT Anti-Cavity Mouthwash
Unisom
Cortizone 10
Kaopectate
Balmex-Diaper Rash OintmentPending the US government’s approval of the merger of Johnson & Johnson and Pfizer Consumer Healthcare, Chattem will acquire five brands divested from the firms. Chattem has announced it expects to take possession of the brands around January 2007. These mature brands will provide $150 million in additional revenue to Chattem per year.On December 21, 2009, Paris-based (France) Sanofi, the worlds fourth largest drugmaker, said it was acquiring Chattem in a $1.9 billion cash deal.